The Experts below are selected from a list of 636 Experts worldwide ranked by ideXlab platform

Stefano Veraldi - One of the best experts on this subject based on the ideXlab platform.

  • Case Report. Erythrasmoid pityriasis versicolor
    Mycoses, 2001
    Co-Authors: A. Gorani, A. Oriani, E. Falconi Klein, Stefano Veraldi
    Abstract:

    A 50-year-old Caucasian man with pityriasis versicolor that was localized almost exclusively in the inguinal folds and was characterized by lesions clinically superimposable on those of Erythrasma is described. Due to these clinical characteristics, it is proposed that this variety of pityriasis versicolor is defined as 'erythrasmoid'.

D. Devliotou-panagiotidou - One of the best experts on this subject based on the ideXlab platform.

Jay Kincannon - One of the best experts on this subject based on the ideXlab platform.

  • Erythrasma Treated With Single-Dose Clarithromycin
    Archives of dermatology, 1998
    Co-Authors: James R. Wharton, Patricia L. Wilson, Jay Kincannon
    Abstract:

    Three patients presented to our clinic with Erythrasma. The results of the clinical examination of each patient showed bilateral patches of erythema in the plicae inguinalis with minimal fine scaling and no central clearing. One patient also had a small superficial erosion in the right plica inguinalis. The results of an examination using Wood light showed coral red fluorescence in each patient. Potassium hydroxide preparations were negative for hyphae or yeast and bacterial cultures grew normal skin flora.

Monica Pau - One of the best experts on this subject based on the ideXlab platform.

  • Pityriasis versicolor on the groin mimicking Erythrasma
    Mycoses, 2004
    Co-Authors: Natalia Aste, Monica Pau
    Abstract:

    Pityriasis versicolor (PV) is a widespread dermatomycosis caused by yeasts. Erythrasma is a superficial bacterial skin disease affecting the major folds of the body, particularly the groin. We report the case of a 45-year-old man, affected by PV, exclusively localized in the inguinal folds and in the inner surface of the thighs, characterized by lesions clinically reproducing Erythrasma. The authors underline the possibility that PV mimics Erythrasma and vice versa, especially in those countries in which both diseases are quite common, and stress the importance of performing a simple mycological examination to avoid gross diagnostic and therapeutic errors.

Renate Reckers‐czaschka - One of the best experts on this subject based on the ideXlab platform.

  • Oxiconazol bei Dermatomykosen — ein doppelblinder, randomisierter Therapievergleich mit Bifonazol/Oxiconazol in Dermatomycosis — a Double-blind, Randomized Comparison with Bifonazol
    Mycoses, 2009
    Co-Authors: W. Wagner, Renate Reckers‐czaschka
    Abstract:

    Summary: In a total of 204 patients with dermatomycosis and Erythrasma, oxiconazole (Oceral Roche, producer Hoffmann—La Roche AG, Grenzach-Wyhlen, (n = 105) and bifonazole (n = 99) were tested in a double—blind, randomized multicenter study. Both preparations were compared in regard to efficacy and tolerance. The period of treatment in both groups was 25 days on average. Mycological sanitation and clinical healing was seen in 81 % and 86 % of these cases respectively. Tolerance has been judged as excellent in 70 % and 71 % of all patients respectively. Local intolerances were noticed in 1 % and 4 % of all patients respectively. Both preparations can be regarded as equally effective and tolerable. Zusammenfassung: An insgesamt 204 Patienten mit Dermatomykosen und Erythrasma wurden Oxiconazol* (n = 105) und Bifonazol (n = 99) im Rahmen einer doppelblinden, randomisierten, multizentrischen Prufung untersucht. Beide Pra parate wurden hinsichtlich Wirksamkeit und Vertraglichkeit verglichen. Die Therapiedauer betrug in den zwei Kollektiven im Mittel 25 Tage. Die mykologische Sanierung und klinische Heilung wurde in 81% bzw. 86 % der Falle erreicht. Die Vertraglichkeit wurde bei 70% aller Patienten als ausgezeichnet beurteilt. Lokale Unvertraglichkeiten traten bei 1% bzw. 4% der Patienten auf. Beide Praparate konnen als gleich gut wirksam und vertraglich bezeichnet werden.